Read Pharmafocus January/February 2018 edition online now!
pharmafile | January 30, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation
With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine a more explosive start to the year, as the dust that had settled on a year characterised by stagnation in the mergers & acquisitions department is swiftly blown away with two major deals in one day: Sanofi shells out $11.6 billion for Bioverativ, and Celgene splashes $9 billion to acquire the rest of Juno Therapeutics. It’s not hard to see the news as a new precedent for 2018 deals in the wake of US tax reform, and it looks set to continue: just days after going to press, Sanofi struck up yet another deal, buying Ablynx for $4.8 billion. You can read the full story on our front page this month.
A slew of engaging stories has blown in since the New Year, particularly the news that, amidst its Brexit woes, the UK boasts the strongest medicine R&D pipeline in Europe, which bodes well for the immediate future of its pharmaceutical and life sciences industries. However, life expectancy growth in the UK has hit a downturn for the first time in 100 years – find out why on page 5.
Across the Atlantic, the US Senate has confirmed the appointment of ex-Lilly US President Alex Azar as Health Secretary, straight off the back of a nomination from President Trump. The decision has not been without controversy, with many questioning how they can trust a man who presided over major price hikes during his time as a pharma executive to make good on the President’s promises to bring down drug prices. You can read the full story on page 7.
Elsewhere, you can read a 2017 retrospective from players all across the pharma and life sciences board, as well as what they have in store for 2018 in our special review feature. And be sure not to miss our in-depth features on the transformative power of AI and the pros and cons of serialisation. We also have interviews from Allergan’s Chief R&D Officer David Nicholson on why the firm is setting itself out to be “the headache company”, and John Ellwood, who discusses his diagnosis and life with multiple myeloma in our new patient experience feature.
Read the Pharmafocus January/February 2018 issue online now!
Related Content
AbbVie initiates phase 3 multiple myeloma trial
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO …
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in …
Sanofi’s Sarclisa accepted for FDA priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental …
